Dachaigh › Scleroderma › Illinois
Sgrùdaidhean clionaigeach Scleroderma ann an Illinois
Tha 11 sgrùdaidhean airson Scleroderma a’ lorg phàirtichean aig làraichean ann an Illinois.
Bailtean ann an Illinois
Teacsa sgrùdaidh oifigeil (Beurla)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Northwestern University, Chicago
- The University of Chicago Medical Center, Chicago
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- University of Illinois Health Outpatient Care Center, Chicago
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT06655155A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
A’ fastadhÌre 1
Aoisean 18 gu 74 · Gach gnè · Air ùrachadh 10 Sult 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Chicago
A’ fastadhÌre 2/3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT05878717A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
A’ fastadhÌre 1
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- The University of Chicago Medical Center (UCMC), Chicago
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
A’ fastadhÌre 2/3
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Chicago
A’ fastadhÌre 1/2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 7 Lùna 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Willowbrook, Willowbrook
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 31 Iuch 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chicago
A’ fastadhÌre 1
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 28 Iuch 2026 · NCT07295847Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 7 Cèit 2025 · NCT05892614Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.